Zanoletti E, Cazzador D, Faccioli C, Gallo S, Denaro L, D'Avella D, Martini A, Mazzoni A
Department of Neurosciences, Otorhinolaryngology Unit, University of Padua, Italy.
Department of Neurosciences, Audiology Unit, University of Padua, Italy.
Acta Otorhinolaryngol Ital. 2018 Aug;38(4):384-392. doi: 10.14639/0392-100X-1756.
The current treatment options for acoustic neuromas (AN) - observation, microsurgery and radiotherapy - should assure no additional morbidity on cranial nerves VII and VIII. Outcomes in terms of disease control and facial function are similar, while the main difference lies in hearing. From 2012 to 2016, 91 of 169 patients (54%) met inclusion criteria for the present study, being diagnosed with unilateral, sporadic, intrameatal or extrameatal AN up to 1 cm in the cerebello-pontine angle; the remaining 78 patients (46%) had larger AN and were all addressed to surgery. The treatment protocol for small AN included observation, translabyrinthine surgery, hearing preservation surgery (HPS) and radiotherapy. Hearing function was assessed according to the Tokyo classification and the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) classification. Sixty-one patients (71%) underwent observation, 19 (22%) HPS and 6 (7%) translabyrinthine surgery; 5 patients were lost to follow-up. Median follow-up was 25 months. In the observation group, 24.6% of patients abandoned the wait-and-see policy for an active treatment; the risk of switching from observation to active treatment was significant for tumour growth (p = 0.0035) at multivariate analysis. Hearing deteriorated in 28% of cases without correlation with tumour growth; the rate of hearing preservation for classes C-D was higher than for classes A-B (p = 0.032). Patients submitted to HPS maintained an overall preoperative hearing class of Tokyo and AAO-HNS in 63% and 68% of cases, respectively. Hearing preservation rate was significantly higher for patients presenting with preoperative favourable conditions (in-protocol) (p = 0.046). A multi-option management for small AN appeared to be an effective strategy in terms of hearing outcomes.
目前,听神经瘤(AN)的治疗选择——观察、显微手术和放射治疗——应确保不会给Ⅶ和Ⅷ颅神经带来额外的发病率。在疾病控制和面部功能方面的结果相似,而主要差异在于听力。2012年至2016年,169例患者中有91例(54%)符合本研究的纳入标准,被诊断为单侧、散发性、内耳道或脑桥小脑角处直径达1 cm的外耳道听神经瘤;其余78例患者(46%)的听神经瘤较大,均接受了手术治疗。小型听神经瘤的治疗方案包括观察、经迷路手术、听力保留手术(HPS)和放射治疗。根据东京分类法和美国耳鼻咽喉-头颈外科学会(AAO-HNS)分类法评估听力功能。61例患者(71%)接受了观察,19例(22%)接受了HPS,6例(7%)接受了经迷路手术;5例患者失访。中位随访时间为25个月。在观察组中,24.6%的患者放弃了观察等待策略而选择积极治疗;在多因素分析中,肿瘤生长导致从观察转为积极治疗的风险具有统计学意义(p = 0.0035)。28%的病例听力下降,与肿瘤生长无关;C-D级的听力保留率高于A-B级(p = 0.032)。接受HPS的患者在东京分类法和AAO-HNS分类法中,分别有63%和68%的病例术前听力等级总体得以维持。术前条件良好(符合方案)的患者听力保留率显著更高(p = 0.046)。就听力结果而言,小型听神经瘤的多选择管理似乎是一种有效的策略。